Vigil Neuroscience (VIGL) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategy

• Focuses on developing microglia-targeted therapies for neurodegenerative diseases, using a precision-based approach with strong genetic and mechanistic links to microglia dysfunction.

• Founded in 2020 after acquiring two TREM2 assets from Amgen, with a pipeline including both a monoclonal antibody and a first-in-class small molecule TREM2 agonist.

• Strategic partnership with Sanofi brought a $40 million investment and extended financial runway into 2026.

ALSP program and clinical development

• Lead antibody, iluzanebart, is in phase II for ALSP, a rare, rapidly progressing, fatal neurodegenerative disease caused by CSF1R mutations affecting microglia.

• Natural history study (ILLUMINATE) mapped disease progression, identified MRI as a dynamic biomarker, and established synthetic control arms for trials.

• Phase II IGNITE study is open-label, enrolling 20 mild to moderately affected patients, with interim data showing slowing of disease progression on MRI and biomarkers.

• FDA discussions focused on MRI as a surrogate endpoint for accelerated approval, with final phase II data expected in the first half of 2025.

Biomarker insights and patient stratification

• MRI changes, especially ventricular volume, correlate with cognitive decline and are quantifiable within six months.

• Soluble CSF1R is reduced in ALSP and increases with treatment, while NfL is elevated and decreases more slowly.

• Some early-stage patients showed stable biomarkers, suggesting potential benefit in maintaining prodromal status.